ALNY - Alnylam Pharmaceuticals Stock Price, News & Analysis

$132.33 0.32 (0.24 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$132.01
Today's Range$129.35 - $133.47
52-Week Range$35.98 - $147.63
Volume771,751 shs
Average Volume1.13 million shs
Market Capitalization$13.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.97

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:ALNY
  • CUSIP: 02043Q10
  • Web: www.alnylam.com
Debt:
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 9.83%
  • Quick Ratio: 9.83%
Sales & Book Value:
  • Annual Sales: $47.16 million
  • Price / Sales: 275.91
  • Book Value: $10.77 per share
  • Price / Book: 12.29
Profitability:
  • Trailing EPS: ($5.25)
  • Net Income: $-410,100,000.00
  • Net Margins: -664.70%
  • Return on Equity: -46.94%
  • Return on Assets: -35.58%
Misc:
  • Employees: 514
  • Outstanding Shares: 98,330,000
 

Frequently Asked Questions for Alnylam Pharmaceuticals (NASDAQ:ALNY)

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.23) by $0.11. The biopharmaceutical company had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company's revenue for the quarter was up 24.8% on a year-over-year basis. During the same period last year, the firm earned ($1.21) EPS. View Alnylam Pharmaceuticals' Earnings History.

When will Alnylam Pharmaceuticals make its next earnings announcement?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for Alnylam Pharmaceuticals.

Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2017?

21 brokerages have issued 1 year price targets for Alnylam Pharmaceuticals' stock. Their predictions range from $56.00 to $220.00. On average, they anticipate Alnylam Pharmaceuticals' stock price to reach $129.40 in the next twelve months. View Analyst Ratings for Alnylam Pharmaceuticals.

What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:

  • 1. FBR & Co analysts commented, "We are initiating coverage of Alnylam Pharmaceuticals, Inc. (ALNY), making it our Alpha Generator pick, with a Buy rating and a 12-month price target of $150 per share, due to our utmost conviction that Alnylam represents a foundational biopharma investment, led by the firm’s hereditary transthyretin amyloidosis (hATTR) franchise." (10/30/2017)
  • 2. Chardan Capital analysts commented, "We reiterate: Ionis is part of our open pair trade that is long Alnylam and short Ionis.) We believe the positive patisiran safety and efficacy data should be considered positive for other players in the RNAi space, including Buy-rated Arbutus Biopharma, which will receive royalties on potential sales of patisiran." (9/25/2017)
  • 3. Needham & Company LLC analysts commented, "Alnylam announced today that dosing of fitusiran, in development for Hemophilia, has been suspended in all clinical trials. A patient death tied to a thrombotic event was reported in ongoing Phase 2 OLE trial and FDA has issued a clinical hold. Alnylam had just initiated a Phase 3 program in Jul 2017. The incident raises questions around safety margin for the drug. Fitusiran is intended to increase thrombin levels closer to normal range. Concerns, however, have been raised around risk of thrombosis if thrombin levels are too high, particularly when used w/ on-demand factor or bypassing agents. Based on available clinical data, we believe fitusiran allows for better control of Hemophilia, but patients and physicians may have a narrower safety window when managing bleeds. Our bias is Alnylam and FDA will reach agreement on a protocol to more closely monitor patients and that clinical development will resume over next 3-6 months. We continue to believe in long-term value of RNAi, but acknowledge greater risk than we anticipated around fitusiran. We have reduced our fitusiran estimates to reflect delayed launch and slower market penetration." (9/7/2017)
  • 4. According to Zacks Investment Research, "Alnylam expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran. It also plans to advance two additional programs into late-stage trials in 2017 and already commenced a phase III study for one of its candidates-fitusiran in July 2017. The company expects to achieve the profile of three marketed products by the end of 2020. Shares of the company have outperformed the Medical-Biomedical/Genetics industry year-to-date. The company’s RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals not only provide it with funds but also take its RNAi technology outside the core focus area. However, the company’s dependence on collaborations for revenues is concerning." (7/17/2017)

Who are some of Alnylam Pharmaceuticals' key competitors?

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:

  • Michael W. Bonney, Independent Chairman of the Board (Age 58)
  • Barry E. Greene, President (Age 53)
  • John M. Maraganore Ph.D., Chief Executive Officer, Director (Age 54)
  • Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer (Age 39)
  • Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President (Age 54)
  • Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development (Age 54)
  • Laurie B. Keating, Senior Vice President, General Counsel, Secretary (Age 62)
  • Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
  • Theresa Heggie, Senior Vice President, Head of Europe and Canada (Age 57)
  • Peter F. Smith Ph.D., Senior Vice President - Early Development (Age 59)

Who owns Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.71%), Gilder Gagnon Howe & Co. LLC (1.22%), Orbimed Advisors LLC (1.17%), First Trust Advisors LP (0.86%), Janus Henderson Group PLC (0.74%) and RTW Investments LP (0.67%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, David E I Pyott, David-Alexandre C Gros, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Michael W Bonney, Philip A Sharp and Sanofi. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Pictet Asset Management Ltd., Wells Fargo & Company MN, Russell Investments Group Ltd., SG Americas Securities LLC, Gilder Gagnon Howe & Co. LLC, Amundi Pioneer Asset Management Inc. and Canada Pension Plan Investment Board. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Michael Mason and Philip A Sharp. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Kornitzer Capital Management Inc. KS, First Trust Advisors LP, WINTON GROUP Ltd, LMR Partners LLP, Candriam Luxembourg S.C.A., Van ECK Associates Corp and Janus Henderson Group PLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Laurie Keating, Michael W Bonney and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy Alnylam Pharmaceuticals stock?

Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $132.01.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $13.01 billion and generates $47.16 million in revenue each year. The biopharmaceutical company earns $-410,100,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. Alnylam Pharmaceuticals employs 514 workers across the globe.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 300 3rd St, CAMBRIDGE, MA 02142-1103, United States. The biopharmaceutical company can be reached via phone at +1-617-5518200 or via email at [email protected]


MarketBeat Community Rating for Alnylam Pharmaceuticals (ALNY)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  677 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  925
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 3 Hold Ratings, 15 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $129.40 (2.21% downside)

Consensus Price Target History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Price Target History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017Piper Jaffray CompaniesReiterated RatingBuy$182.00N/AView Rating Details
11/9/2017Cowen and CompanyReiterated RatingBuy$151.00N/AView Rating Details
11/9/2017Morgan StanleyBoost Price TargetEqual Weight$101.00 -> $130.00N/AView Rating Details
11/9/2017J P Morgan Chase & CoUpgradeNeutral -> OverweightN/AView Rating Details
11/8/2017B. RileyLower Price TargetBuy$220.00N/AView Rating Details
11/8/2017Barclays PLCBoost Price TargetOverweight$127.00 -> $158.00N/AView Rating Details
11/3/2017Credit Suisse GroupBoost Price TargetOutperform$123.00 -> $151.00N/AView Rating Details
11/3/2017Needham & Company LLCReiterated RatingBuy -> Buy$125.00 -> $152.00N/AView Rating Details
10/30/2017FBR & CoInitiated CoverageBuy -> Buy$150.00N/AView Rating Details
10/2/2017Goldman Sachs Group, Inc. (The)UpgradeNeutral -> Buy$62.00 -> $163.00MediumView Rating Details
9/26/2017Jefferies Group LLCBoost Price TargetPositive -> Buy$102.00 -> $130.00LowView Rating Details
9/25/2017Chardan CapitalReiterated RatingBuy$124.00LowView Rating Details
9/22/2017BMO Capital MarketsReiterated RatingOutperform$99.00 -> $134.00LowView Rating Details
9/21/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$90.00 -> $146.00LowView Rating Details
9/21/2017Sanford C. BernsteinReiterated RatingOutperform -> Buy$94.00 -> $135.00LowView Rating Details
9/20/2017Stifel NicolausReiterated RatingHold$56.00 -> $83.00LowView Rating Details
9/20/2017JMP SecuritiesBoost Price TargetOutperform$101.00 -> $128.00LowView Rating Details
9/15/2017InstinetInitiated CoverageReduce -> Reduce$56.00LowView Rating Details
9/14/2017NomuraInitiated CoverageReduce$56.00HighView Rating Details
9/8/2017Leerink SwannReiterated RatingMarket Perform$83.00 -> $72.00LowView Rating Details
6/2/2017Janney Montgomery ScottInitiated CoverageUnderperform -> Sell$69.70 -> $67.00LowView Rating Details
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldN/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Earnings by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Earnings History by Quarter for Alnylam Pharmaceuticals (NASDAQ ALNY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2018N/AView Earnings Details
11/7/2017Q3 2017($1.23)($1.34)$28.15 million$17.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.22)($1.34)$23.86 million$15.93 millionViewListenView Earnings Details
5/5/2017Q1 2017($1.22)($1.25)$22.91 million$19.00 millionViewN/AView Earnings Details
2/8/2017Q416($1.34)($1.32)$10.66 million$17.50 millionViewListenView Earnings Details
11/2/2016Q316($1.14)($1.21)$9.14 million$13.70 millionViewN/AView Earnings Details
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.65)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.66)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.54)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($1.18)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
2017 EPS Consensus Estimate: ($4.98)
2018 EPS Consensus Estimate: ($5.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.30)($1.33)
Q2 20172($1.20)($1.15)($1.18)
Q3 20173($1.25)($1.09)($1.17)
Q4 20174($1.43)($1.09)($1.30)
Q1 20182($1.53)($1.25)($1.39)
Q2 20183($1.64)($1.50)($1.59)
Q3 20183($1.45)($0.69)($1.13)
Q4 20183($1.41)($0.14)($0.99)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alnylam Pharmaceuticals (NASDAQ ALNY)

Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 86.04%
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Insider Trades by Quarter for Alnylam Pharmaceuticals (NASDAQ ALNY)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2017John MaraganoreCEOSell74,000$126.86$9,387,640.00View SEC Filing  
11/2/2017Dennis A AusielloDirectorSell20,000$130.00$2,600,000.00View SEC Filing  
10/30/2017Akshay VaishnawEVPSell33,666$121.46$4,089,072.36View SEC Filing  
10/2/2017Barry E GreenePresidentSell85,316$125.00$10,664,500.00View SEC Filing  
9/20/2017Barry E GreenePresidentSell76,815$100.00$7,681,500.00View SEC Filing  
5/31/2017SanofiMajor ShareholderBuy297,501$71.87$21,381,396.87View SEC Filing  
5/30/2017Laurie KeatingSVPBuy11,500$65.35$751,525.00View SEC Filing  
5/23/2017Akshay VaishnawEVPSell11,000$75.00$825,000.00View SEC Filing  
5/16/2017Michael MasonVPSell9,375$70.00$656,250.00View SEC Filing  
5/15/2017Akshay VaishnawSVPSell43,750$65.00$2,843,750.00View SEC Filing  
1/25/2017Philip A SharpDirectorSell15,000$37.95$569,250.00View SEC Filing  
1/18/2017Philip A SharpDirectorSell15,000$37.83$567,450.00View SEC Filing  
11/30/2016Akshay VaishnawCMOSell29,165$44.99$1,312,133.35View SEC Filing  
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Alnylam Pharmaceuticals (NASDAQ ALNY)

Source:
DateHeadline
BRIEF-FDA grants Alnylam breakthrough therapy designation for PatisiranBRIEF-FDA grants Alnylam breakthrough therapy designation for Patisiran
www.reuters.com - November 21 at 4:18 PM
Alnylam's RNAi Candidate Gains Breakthrough Therapy StatusAlnylam's RNAi Candidate Gains Breakthrough Therapy Status
finance.yahoo.com - November 21 at 4:18 PM
A Look at Alnylam Pharmaceuticals" Rolling NDAA Look at Alnylam Pharmaceuticals" Rolling NDA
finance.yahoo.com - November 21 at 4:18 PM
Alnylam Sets Its Eyes On The Finish Line - Seeking AlphaAlnylam Sets Its Eyes On The Finish Line - Seeking Alpha
seekingalpha.com - November 20 at 5:10 PM
U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with PolyneuropathyU.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy
finance.yahoo.com - November 20 at 5:10 PM
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore Sells 74,000 SharesAlnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore Sells 74,000 Shares
www.americanbankingnews.com - November 17 at 7:47 PM
FDA OKs Roches Hemlibra for hemophilia A - Seeking AlphaFDA OKs Roche's Hemlibra for hemophilia A - Seeking Alpha
seekingalpha.com - November 17 at 3:27 PM
Alnylam Starts Rolling NDA Submission for RNAi Candidate - NasdaqAlnylam Starts Rolling NDA Submission for RNAi Candidate - Nasdaq
www.nasdaq.com - November 17 at 3:27 PM
Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters ... - Business Wire (press release)Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters ... - Business Wire (press release)
www.businesswire.com - November 17 at 3:27 PM
Alnylam Pharmaceuticals, Inc.s Pipeline Progresses, Approval Next - Motley FoolAlnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next - Motley Fool
www.fool.com - November 17 at 3:27 PM
Alnylam Pharmaceuticals, Inc. (ALNY) Earns "Buy" Rating from Piper Jaffray CompaniesAlnylam Pharmaceuticals, Inc. (ALNY) Earns "Buy" Rating from Piper Jaffray Companies
www.americanbankingnews.com - November 17 at 1:12 PM
New Research: Key Drivers of Growth for Great Plains Energy, Flowers Foods, Hasbro, Acadia Healthcare, DXC Technology, and Alnylam Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for Great Plains Energy, Flowers Foods, Hasbro, Acadia Healthcare, DXC Technology, and Alnylam Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - November 17 at 10:50 AM
Alnylam Starts Rolling NDA Submission for RNAi CandidateAlnylam Starts Rolling NDA Submission for RNAi Candidate
finance.yahoo.com - November 17 at 10:50 AM
Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesAlnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - November 16 at 8:59 PM
Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?
finance.yahoo.com - November 16 at 3:58 PM
Alnylam Pharmaceuticals, Inc. (ALNY) Given Average Recommendation of "Buy" by BrokeragesAlnylam Pharmaceuticals, Inc. (ALNY) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 16 at 3:50 PM
Why is Alnylams (ALNY) Stock Up More Than 200% this Year?Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?
www.zacks.com - November 16 at 11:04 AM
Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval NextAlnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
finance.yahoo.com - November 16 at 11:04 AM
Alnylam Pharmaceuticals, Inc.s Pipeline Progresses, Approval NextAlnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
www.fool.com - November 15 at 4:50 PM
Alnylam Pharma Begins Public Offering To Raise Proceeds Of About $675 MlnAlnylam Pharma Begins Public Offering To Raise Proceeds Of About $675 Mln
www.rttnews.com - November 14 at 4:15 PM
BRIEF-EMA grants Alnylam accelerated assessment of rare disease drugBRIEF-EMA grants Alnylam accelerated assessment of rare disease drug
www.businessinsider.com - November 14 at 4:15 PM
Alnylam Pharma (ALNY) Prices 5.6M Share Common Offering at $125/ShAlnylam Pharma (ALNY) Prices 5.6M Share Common Offering at $125/Sh
www.streetinsider.com - November 14 at 4:15 PM
Alnylam Pharmaceuticals Announces Proposed Public Offering of $675,000,000 of Common StockAlnylam Pharmaceuticals Announces Proposed Public Offering of $675,000,000 of Common Stock
finance.yahoo.com - November 14 at 4:15 PM
European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) AmyloidosisEuropean Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis
finance.yahoo.com - November 14 at 4:15 PM
Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMAAlnylam RNAi Drug Gets Accelerated Assessment Grant From EMA
finance.yahoo.com - November 14 at 4:15 PM
Arbutus LNP Licensee Alnylam Receives Accelerated Assessment ... - GlobeNewswire (press release)Arbutus' LNP Licensee Alnylam Receives Accelerated Assessment ... - GlobeNewswire (press release)
globenewswire.com - November 14 at 2:50 AM
Alnylam Pharma (ALNY) Granted Accelerated Assessment of ... - StreetInsider.comAlnylam Pharma (ALNY) Granted Accelerated Assessment of ... - StreetInsider.com
www.streetinsider.com - November 14 at 2:50 AM
Alnylam Pharmaceuticals Prices Public Offering of Common StockAlnylam Pharmaceuticals Prices Public Offering of Common Stock
finance.yahoo.com - November 14 at 2:49 AM
Alnylam Pharma (ALNY) Announces Successful Outcome Following FDA Type A Meeting on Fitusiran ProgramAlnylam Pharma (ALNY) Announces Successful Outcome Following FDA Type A Meeting on Fitusiran Program
www.streetinsider.com - November 10 at 2:28 PM
Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017
finance.yahoo.com - November 10 at 2:27 PM
The Forbes Healthcare Summit 2017: The Draft AgendaThe Forbes Healthcare Summit 2017: The Draft Agenda
finance.yahoo.com - November 10 at 2:27 PM
FY2017 EPS Estimates for Alnylam Pharmaceuticals, Inc. Reduced by Analyst (ALNY)FY2017 EPS Estimates for Alnylam Pharmaceuticals, Inc. Reduced by Analyst (ALNY)
www.americanbankingnews.com - November 10 at 8:34 AM
Alnylam Pharmaceuticals, Inc. (ALNY) Forecasted to Post FY2017 Earnings of ($5.07) Per ShareAlnylam Pharmaceuticals, Inc. (ALNY) Forecasted to Post FY2017 Earnings of ($5.07) Per Share
www.americanbankingnews.com - November 10 at 8:34 AM
FY2017 EPS Estimates for Alnylam Pharmaceuticals, Inc. Lowered by Leerink Swann (ALNY)FY2017 EPS Estimates for Alnylam Pharmaceuticals, Inc. Lowered by Leerink Swann (ALNY)
www.americanbankingnews.com - November 10 at 8:34 AM
ETFs with exposure to Alnylam Pharmaceuticals, Inc. : November 9, 2017ETFs with exposure to Alnylam Pharmaceuticals, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 4:48 PM
Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in HemophiliaAlnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia
finance.yahoo.com - November 9 at 4:48 PM
Alnylam Pharmaceuticals, Inc. (ALNY) Given Buy Rating at Cowen and CompanyAlnylam Pharmaceuticals, Inc. (ALNY) Given Buy Rating at Cowen and Company
www.americanbankingnews.com - November 9 at 3:42 PM
Alnylam Pharmaceuticals, Inc. Expected to Earn Q1 2018 Earnings of ($1.53) Per Share (ALNY)Alnylam Pharmaceuticals, Inc. Expected to Earn Q1 2018 Earnings of ($1.53) Per Share (ALNY)
www.americanbankingnews.com - November 9 at 11:46 AM
Alnylam Pharma (ALNY) Initiates ENVISION Phase 3 Clinical Study with Givosiran to Treat AHPsAlnylam Pharma (ALNY) Initiates ENVISION Phase 3 Clinical Study with Givosiran to Treat AHPs
www.streetinsider.com - November 8 at 5:58 PM
EARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q3 Earnings Report
www.rttnews.com - November 8 at 5:58 PM
BRIEF-Alnylam Pharmaceuticals Q3 non-gaap loss per share $1.06BRIEF-Alnylam Pharmaceuticals Q3 non-gaap loss per share $1.06
www.reuters.com - November 8 at 5:58 PM
Alnylams (ALNY) Q3 Earnings, Revenues Miss EstimatesAlnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates
www.nasdaq.com - November 8 at 5:58 PM
Alnylam Pharmaceuticals, Inc. (ALNY) Issues  Earnings ResultsAlnylam Pharmaceuticals, Inc. (ALNY) Issues Earnings Results
www.americanbankingnews.com - November 8 at 3:02 PM
Edited Transcript of ALNY earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of ALNY earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 6:25 AM
 Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $37.02 Million Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $37.02 Million
www.americanbankingnews.com - November 8 at 4:50 AM
Alnylam Pharmaceuticals (ALNY) Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAlnylam Pharmaceuticals (ALNY) Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 7 at 10:24 PM
Alnylam Pharmaceuticals (ALNY) a Buy on Healthy Quant Score - Investorplace.comAlnylam Pharmaceuticals (ALNY) a Buy on Healthy Quant Score - Investorplace.com
investorplace.com - November 7 at 5:23 PM
Is a Surprise Coming for Alnylam Pharmaceuticals (ALNY) This Earnings Season? - Yahoo FinanceIs a Surprise Coming for Alnylam Pharmaceuticals (ALNY) This Earnings Season? - Yahoo Finance
finance.yahoo.com - November 7 at 5:23 PM
Alnylam launches late-stage study assessing givosiran in AHPs ... - Seeking AlphaAlnylam launches late-stage study assessing givosiran in AHPs ... - Seeking Alpha
seekingalpha.com - November 7 at 5:23 PM
Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity - Business Wire (press release)Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity - Business Wire (press release)
www.businesswire.com - November 7 at 5:23 PM

Social Media

Financials

Chart

Alnylam Pharmaceuticals (NASDAQ ALNY) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.